Literature DB >> 15136794

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.

T D Gould1, J A Quiroz, J Singh, C A Zarate, H K Manji.   

Abstract

Bipolar disorder afflicts approximately 1-3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136794     DOI: 10.1038/sj.mp.4001518

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  73 in total

1.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Proteomic analysis of excretory secretory products from Clonorchis sinensis adult worms: molecular characterization and serological reactivity of a excretory-secretory antigen-fructose-1,6-bisphosphatase.

Authors:  Minghui Zheng; Kunhua Hu; Wei Liu; Xuchu Hu; Fengyu Hu; Lisi Huang; Peng Wang; Yue Hu; Yan Huang; Wenfang Li; Chi Liang; Xingfeng Yin; Qingyu He; Xinbing Yu
Journal:  Parasitol Res       Date:  2011-03-22       Impact factor: 2.289

3.  Combined diffusion tensor imaging and transverse relaxometry in early-onset bipolar disorder.

Authors:  Atilla Gönenç; Jean A Frazier; David J Crowley; Constance M Moore
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-10-29       Impact factor: 8.829

Review 4.  Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement.

Authors:  Todd D Gould; Haim Einat
Journal:  Neurosci Biobehav Rev       Date:  2007-05-31       Impact factor: 8.989

5.  A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation.

Authors:  Joshua P Frederick; A Tsahai Tafari; Sheue-Mei Wu; Louis C Megosh; Shean-Tai Chiou; Ryan P Irving; John D York
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

6.  [Bipolar depression. Epidemiology, etiopathogenesis, and course].

Authors:  S Haack; A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

7.  Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.

Authors:  Daniel P Dickstein; Kenneth E Towbin; Jan Willem Van Der Veen; Brendan A Rich; Melissa A Brotman; Lisa Knopf; Laura Onelio; Daniel S Pine; Ellen Leibenluft
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-02       Impact factor: 2.576

8.  Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation.

Authors:  Jean-Michel Aubry; Michèle Schwald; Eladia Ballmann; Félicien Karege
Journal:  Psychopharmacology (Berl)       Date:  2009-05-14       Impact factor: 4.530

9.  Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides.

Authors:  Hee Jung Kim; Stanley A Thayer
Journal:  Mol Pharmacol       Date:  2009-02-02       Impact factor: 4.436

10.  Carbamazepine extended-release capsules in bipolar disorder.

Authors:  Richard H Weisler
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.